Company intelligence / Profile preview

Minaris Regenerative Medicine

Allendale, New Jersey, United Statesrm.minaris.com ↗

Ownership: Private
Development stage: Commercial

Overview

Minaris Regenerative Medicine is a leading global CDMO with over 25 years of experience in the development, clinical, and commercial manufacturing of cell and gene therapies. It has supported more than 180 clients with over 100 technology transfers, including the recent commercial launch of LYFGENIA for sickle cell disease developed by bluebird bio at its Allendale, NJ facility.

Modalities: Cell therapyGene therapy
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

LYFGENIA

Commercial

Indications: Sickle cell disease

Partnerships

bluebird bio (commercial manufacture of LYFGENIA)Cryoport Inc. (strategic partnership for logistics support in CGT)

Beyond the preview

Go deeper on Minaris Regenerative Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minaris Regenerative Medicine.